[18F]FAPI-04在肝内胆管癌分期与治疗管理中的作用:与[18F]FDG PET/CT的前瞻性对比
前瞻性纳入23例经组织学确诊的肝内胆管癌患者,比较[18F]FAPI-04与[18F]FDG PET/CT对389个病灶的检出率及摄取值。FAPI-04对肝内病灶、淋巴结转移和骨转移检出率更高,骨转移SUVmax与TBR更高;6/23例(26.1%)患者治疗计划因FAPI-04改变。作者认为FAPI-04 PET/CT可能是肝内胆管癌诊断与分期的有前景技术。
要点
- FAPI-04对肝内病灶检出率86.3% vs FDG 78.2%(P=0.040),淋巴结转移85.2% vs 68.2%(P=0.007),骨转移100% vs 70.5%(P<0.001)
- 非胆管炎肝内病灶FAPI-04的SUVmax 8.7 vs FDG 6.4(P<0.001),TBR 8.0 vs 3.5(P<0.001)
- 6例梗阻性胆管炎患者FDG的SUVmax 14.7 vs FAPI-04 8.4(P<0.001),TBR 7.4 vs 2.8(P<0.001)
核心结论
- [18F]FAPI-04 PET/CT在肝内病灶、淋巴结转移和远处转移(尤其是骨)中检出率和放射性示踪剂摄取高于[18F]FDG PET/CT。
- 作者认为[18F]FAPI-04 PET/CT可能是肝内胆管癌诊断与分期的有前景技术。
研究设计与样本
- 前瞻性分析经组织学确诊的肝内胆管癌患者,均行[18F]FDG和[18F]FAPI-04 PET/CT。
- 共纳入23例患者、389个病灶。
- 采用配对Wilcoxon符号秩检验和Mann-Whitney U检验比较两种方法的SUVmax、TBR、MTV、TLG、FTV、TLF,McNemar检验评估诊断准确性。
- 临床试验注册号NCT05485792,注册日期2022年8月1日,回顾性注册。
主要发现
- [18F]FAPI-04较[18F]FDG检出率更高:肝内病灶86.3% vs 78.2%(P=0.040),淋巴结转移85.2% vs 68.2%(P=0.007),腹膜转移100% vs 93.8%,骨转移100% vs 70.5%(P<0.001)。
- 非胆管炎肝内病灶:FAPI-04的SUVmax 8.7 vs FDG 6.4(P<0.001),TBR 8.0 vs 3.5(P<0.001),FTV vs MTV 41.3 vs 12.4(P<0.001),TLF vs TLG 223.5 vs 57.0(P<0.001)。
- 淋巴结转移:FAPI-04的SUVmax 6.5 vs FDG 5.5(P=0.042),TBR 5.4 vs 3.9(P<0.001),FTV vs MTV 2.0 vs 1.5(P=0.026),TLF vs TLG 9.0 vs 7.8(P=0.024)。
- 骨转移:FAPI-04的SUVmax 9.7 vs FDG 5.25(P<0.001),TBR 10.8 vs 3.0(P<0.001),TLF vs TLG 9.8 vs 4.2(P<0.001)。
- 6例梗阻性胆管炎患者中,FDG的SUVmax 14.7 vs FAPI-04 8.4(P<0.001),TBR 7.4 vs 2.8(P<0.001)。
关键数值与推荐
- 肝内病灶检出率:[18F]FAPI-04 86.3% vs [18F]FDG 78.2%(P=0.040)。
- 淋巴结转移检出率:[18F]FAPI-04 85.2% vs [18F]FDG 68.2%(P=0.007)。
- 腹膜转移检出率:[18F]FAPI-04 100% vs [18F]FDG 93.8%。
- 骨转移检出率:[18F]FAPI-04 100% vs [18F]FDG 70.5%(P<0.001)。
- 非胆管炎肝内病灶SUVmax:[18F]FAPI-04 8.7 vs [18F]FDG 6.4(P<0.001);TBR:8.0 vs 3.5(P<0.001)。
临床怎么用
- 作者认为[18F]FAPI-04 PET/CT可能是肝内胆管癌诊断与分期的有前景技术。
- [18F]FAPI-04较[18F]FDG使6/23例(26.1%)患者的计划治疗发生改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has some limitations in diagnosis of Intrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS: Patients with histologically confirmed ICC who underwent both [18F]FDG and 18F-labeled fibroblast-activation protein inhibitors ([18F]FAPI)-04 PET/CT were prospectively analyzed. The maximum standard uptake value (SUVmax), tumor-to-background ratio (TBR), metabolic tumor volume (MTV), total lesion glycolysis (TLG), [18F]FAPI-avid tumor volume (FTV), total lesion fibroblast activation protein expression (TLF) were compared between the two modalities by paired Wilcoxon signed-rank test and Mann-Whitney U test, and McNemar's test was used to assess the diagnostic accuracy between the two techniques. RESULTS: In total, 23 patients with 389 lesions were included. Compared to [18F]FDG, [18F]F-FAPI-04 PET/CT demonstrated a higher detection rate for intrahepatic lesions (86.3% vs. 78.2% P = 0.040), lymph node metastases (85.2% vs. 68.2%, P = 0.007), peritoneal metastases (100% vs. 93.8%), and bone metastases (100% vs. 70.5%, P < 0.001). [18F]FAPI-04 PET showed higher SUVmax, TBR and greater tumor burden values than [18F]FDG PET in non-cholangitis intrahepatic lesions (SUVmax: 8.7 vs. 6.4, P < 0.001; TBR: 8.0 vs. 3.5, P < 0.001; FTV vs. MTV: 41.3 vs. 12.4, P < 0.001; TLF vs. TLG: 223.5 vs. 57.0, P < 0.001), lymph node metastases (SUVmax: 6.5 vs. 5.5, P = 0.042; TBR: 5.4 vs. 3.9, P < 0.001; FTV vs. MTV: 2.0 vs. 1.5, P = 0.026; TLF vs. TLG: 9.0 vs. 7.8 P = 0.024), and bone metastases (SUVmax: 9.7 vs. 5.25, P < 0.001; TBR: 10.8 vs. 3.0, P < 0.001; TLF vs. TLG: 9.8 vs. 4.2, P < 0.001). However, [18F]FDG showed higher radiotracer uptake (SUVmax: 14.7 vs. 8.4, P < 0.001; TBR: 7.4 vs. 2.8, P < 0.001) than [18F]FAPI-04 PET/CT for 6 patients with obstructive cholangitis. [18F]FAPI-04 PET/CT yielded a change in planned therapy in 6 of 23 (26.1%) patients compared with [18F]FDG. CONCLUSIONS: [18F]FAPI-04 PET/CT had higher detection rate and radiotracer uptake than [18F]FDG PET/CT in intrahepatic lesions, lymph node metastases, and distant metastases, especially in bone. Therefore, [18F]FAPI-04 PET/CT may be a promising technique for diagnosis and staging of ICC. TRIAL REGISTRATION: Clinical Trials, NCT05485792. Registered 1 August 2022, retrospectively registered, https//clinicaltrials.gov/study/NCT05485792?cond=NCT05485792&rank=1.
引用
- Liang J, Jiang S, Song J, et al. Role of [18F]FAPI-04 in staging and therapeutic management of intrahepatic cholangiocarcinoma: prospective comparison with [18F]FDG PET/CT. EJNMMI Res. 2024. PMID: 39256297. doi:10.1186/s13550-024-01145-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。